[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630472":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":21,"centralContacts":22,"locations":28,"responsibleParty":46,"collaborators":21,"id":48,"slug":21,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":21,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":21,"overallStatus":31,"whyStopped":21,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"patients with Autoimmune encephalitis","EXPERIMENTAL",[12],"Other: TEP with radioligand EAI 714",{"label":14,"type":10,"description":14,"interventionNames":15},"control",[12],[17],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"TEP with radioligand EAI 714","60-minutes \\[18F\\]-DPA-714 PET imaging",[14,9],null,[23],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"Marie Rafiq, MD","CONTACT","+33 561779491","rafiq.m@chu-toulouse.fr",[29],{"facility":30,"status":31,"city":32,"state":21,"zip":21,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"University Hospital","RECRUITING","Toulouse","France",{"type":35,"coordinates":36},"Point",[37,38],1.44367,43.60426,{"lat":38,"lon":37},[41,43],{"name":42,"role":25,"phone":21,"phoneExt":21,"email":27},"Marie RAFIQ, MD",{"name":44,"role":45,"phone":21,"phoneExt":21,"email":21},"Marie rafiq, MD","PRINCIPAL_INVESTIGATOR",{"type":47,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100630472",false,"NCT07488117","Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?","EAI-714","Inclusion Criteria:\n\n* Age 18-80 years;\n* meeting clinical criteria for \"possible\" AE with identified antibodies;\n* newly diagnosed with symptoms \\\u003C6 months;\n* no second-line immunosuppressive treatment;\n* high or mixed TSPO binding affinity phenotype.\n\nExclusion Criteria:\n\n* Pregnant women;\n* contraindications to MRI;\n* known allergic reaction to \\[18F\\]-DPA-714; legal protection measure;\n* paraneoplastic syndrome following immune checkpoint inhibitor therapy.",true,"ALL","18 Years","80 Years",{"count":59,"type":60},40,"ESTIMATED","INTERVENTIONAL",[63],"PHASE2","This study aims to evaluate the effectiveness of \\[18F\\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \\[18F\\]-DPA-714 binding in AE patients to healthy controls.",[66],"Autoimmune Encephalitis (AE)","2026-05-06",{"date":69,"type":70},"2026-05-11","ACTUAL",{"date":72,"type":70},"2026-03-31",{"date":74,"type":60},"2028-01",{"name":5,"class":6},1]